Ramaswamy's rare-disease offshoot Enzyvant poaches Alexion exec Rachelle Jacques to replace Alvin Shih at the helm
Alexion’s Rachelle Jacques is jumping ship to another rare disease biotech with a big promotion: CEO of Enzyvant Sciences, which was forged out of Vivek …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
